
NCTFACT BOOK

1983

National
Cancer
Program

U.S. DEPARTMENT
OF HEALTH AND
HUMAN SERVICES

Public Health
Service

National
Institutes of
Health

NCI FACT BOOK

National Cancer Program
1983

FOR ADMINISTRATIVE USE

U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service National Institutes of Health

PREFACE

The information set forth in this publication is compiled and amended annually by the Financial Management Staff of the National Cancer Institute and is intended primarily for use by members of the Institute staff, the principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Manager, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland 20205.

TABLE OF CONTENTS

	PAGE
Preface	ii
GENERAL INFORMATION	
Directory of Personnel	iv
Historical Data: Legislative Highlights	1
Historical Events	2
Director NCP/NCI – President’s Cancer Panel	3
National Cancer Advisory Board	4
Organizational Tables: National Cancer Institute	5
Office of the Director	6
Division of Cancer Biology and Diagnosis	7
Division of Cancer Treatment	8
Division of Cancer Etiology	10
Division of Cancer Prevention and Control	11
Division of Extramural Activities	12
5-Year Relative Survival Rates	13
Statistical Tables: Number of Deaths for the Five Leading Cancer Sites – 1980	14
Relationship of Cancer to Leading Causes of Death in the United States – 1980	14
Estimated Cancer Deaths and New Cases by Sex and Site – 1983	15
Research Positions at the National Cancer Institute	16
NCI Intramural Review Process	18
Building Location and Square Footage	19
BUDGET DATA	
Major Steps in the Budget Formulation Review Process	20
Estimated Total National Resources for Cancer Research and Cancer Control – Fiscal Year 1983	21
NCI Program Structure – Fiscal Year 1983	22
National Cancer Institute Budget History by Group	23
National Cancer Institute Budget History by Mechanisms	24
NCI Research Programs – Fiscal Year 1983	26
NCI Extramural Funds – Fiscal Year 1983	27
Total NCI Dollars by Mechanisms – Fiscal Year 1983	28
Cancer Control Obligations by Mechanism – Fiscal Years 1974-1983	29
Reimbursement to NIH Management Fund – Fiscal Year 1983	30
GRANTS AND CONTRACTS	
NCI Grant Process	31
NCI Contract Award Process	32
State Distribution of Grants and Contracts – Fiscal Year 1983	33
Distribution of Cancer Control Grants and Contracts – Fiscal Year 1983	34
Institutions Receiving More Than \$2,000,000 from the NCI – Fiscal Year 1983	35
Distribution of NCI Contracts – Fiscal Year 1983	37
Distribution of the Grant Dollar – Fiscal Year 1983	38
Foreign Research Grants and Contracts – Fiscal Year 1983	39
HISTORY TABLES	
Appropriations of the NCI 1983-1984	40
Comparison of Dollars, Positions and Space	41
NCI Obligations and Outlays – 1976-1983	42
NCI Total Research Projects – 1978-1983	43

DIRECTORY OF PERSONNEL

NATIONAL CANCER INSTITUTE
 NATIONAL INSTITUTES OF HEALTH
 BETHESDA, MARYLAND 20205

NIH Operator
 496-4000
 Area Code 301

		DIRECT-IN DIALING
DIRECTOR	BUILDING 31	
Dr. Vincent T. DeVita, Jr.*	11-A-52	496-5615
DIRECTOR, STAFF OPERATIONS	BUILDING 31	
Ms. Iris Schneider	11-A-46	496-5534
MANAGER, EQUAL EMPLOYMENT OPPORTUNITY	BUILDING 31	
Ms. Maxine I. Richardson	10-A-33	496-6266
DEPUTY DIRECTOR	BUILDING 31	
Dr. Jane Henney*	11-A-52	496-3505
ASSOCIATE DIRECTOR	BUILDING 31	
Dr. Peter Fischinger*	11-A-19	496-1927
ASSISTANT DIRECTOR	BUILDING 31	
Dr. Elliott Stonehill	11-A-23	496-1148
ASSOCIATE DIRECTOR FOR PROGRAM PLANNING AND ANALYSIS	BUILDING 31	
Mr. Louis M. Carrese	10-A-52	496-6445
CHIEF, MANAGEMENT INFORMATION SYSTEMS BRANCH	BUILDING 31	
Ms. Betty Ann Sullivan	10-A-48	496-1038
CHIEF, SYSTEMS PLANNING BRANCH	BUILDING 31	
Ms. Barbara Murray	10-A-49	496-5515
LEGISLATIVE ANALYST/CONGRESSIONAL LIAISON	BUILDING 31	
Dr. Mary Knipmeyer	10-A-52	496-5217
ASSOCIATE DIRECTOR FOR CANCER COMMUNICATIONS	BUILDING 31	
Mr. J. Paul Van Nevel	10-A-29	496-6631
CHIEF, INFORMATION RESOURCES BRANCH	BUILDING 31	
Mr. Joseph Bangiolo	10-A-18	496-6756
CHIEF, REPORTS AND INQUIRIES BRANCH	BUILDING 31	
Dr. Robert M. Hadsell	10-A-29	496-6631
CHIEF, INFORMATION PROJECTS BRANCH	BUILDING 31	
Mr. Robert Denniston	4-B-39	496-6793
ASSOCIATE DIRECTOR FOR INTERNATIONAL AFFAIRS	BUILDING 31	
Dr. Ihor J. Masnyk, Acting	4-A-49	496-4761
ASSOCIATE DIRECTOR FOR ADMINISTRATIVE MANAGEMENT	BUILDING 31	
Mr. Philip Amoruso*	11-A-49	496-5737
Mr. Robert M. Namovicz, Deputy	BUILDING 31 11-A-51	496-5737
CHIEF, ADMINISTRATIVE SERVICES BRANCH	BUILDING 31	
Mr. James Prather	11-A-29	496-5801
CHIEF, FINANCIAL MANAGEMENT BRANCH	BUILDING 31	
Mr. John P. Hartinger	11-A-18	496-5803
CHIEF, PERSONNEL MANAGEMENT BRANCH	BUILDING 31	
Ms. Marianne Wagner	3-A-19	496-3337
CHIEF, RESEARCH CONTRACTS BRANCH	BLAIR BUILDING	
Mr. John Campbell	332	427-8810
CHIEF, MANAGEMENT POLICY BRANCH	BUILDING 31	
Mr. Thomas L. Kearns	4-B-55	496-6985
CHIEF, GRANTS ADMINISTRATION BRANCH	WESTWOOD BUILDING	
Mr. Leo F. Buscher, Jr.	8-A-18	496-7753
CHIEF, EXTRAMURAL FINANCIAL DATA BRANCH	WESTWOOD BUILDING	
Mr. Robert E. Spallone	8-A-03	496-7660

*NCI Executive Committee Members

**DIRECT-IN
DIALING**

FREDERICK CANCER RESEARCH CENTER	FREDERICK, MARYLAND	
GENERAL MANAGER/PROJECT OFFICER	BUILDING	
Dr. Berge Hampar	427	FTS-8-935-1108
DEPUTY GENERAL MANAGER	BUILDING	
Mr. Richard Carter	427	FTS-8-935-1106

DIRECTOR, DIVISION OF CANCER ETIOLOGY	BUILDING 31	
Dr. Richard Adamson*	11-A-03	496-6618
ADMINISTRATIVE OFFICER	BUILDING 31	
Mr. Stephen Ficca	11-A-11	496-6556

DIRECTOR, DIVISION OF CANCER BIOLOGY AND DIAGNOSIS	BUILDING 31	
Dr. Alan S. Rabson*	3-A-03	496-4345
ADMINISTRATIVE OFFICER	BUILDING 31	
Mr. Larry D. Willhite	3-A-05	496-3381

DIRECTOR, DIVISION OF CANCER TREATMENT	BUILDING 31	
Dr. Bruce Chabner*	3-A-52	496-4291
ADMINISTRATIVE OFFICER	BUILDING 31	
Mr. Michael Goldrich	3-A-50	496-2775

DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES	BUILDING 31	
Mrs. Barbara Bynum*	10-A-03	496-5147
ADMINISTRATIVE OFFICER	BUILDING 31	
Ms. Jean Stein	10-A-10	496-5915

DIRECTOR, DIVISION OF CANCER PREVENTION AND CONTROL	BUILDING 31	
Dr. Peter Greenwald*	4-A-32	496-6616
ADMINISTRATIVE OFFICER	BUILDING 31	
Mr. Nicholas Olimpico	4-A-46	496-9606

*NCI Executive Committee Members

NATIONAL CANCER INSTITUTE HISTORICAL DATA

LEGISLATIVE HIGHLIGHTS

July 23, 1937—The National Cancer Institute Act, introduced by Congressman Warren G. Magnuson, was passed by Congress. An appropriation of \$700,000 for each fiscal year was authorized.

July 1, 1944—The Public Health Service Act, Public Law 410, 78th Congress provided that “The National Cancer Institute shall be a division in the National Institutes of Health.” The act also revised and consolidated many revisions into a single law. The limit of \$700,000 annual appropriation was removed.

January 22, 1971—In his State of the Union Message, President Nixon announced that he would ask for the appropriation of an additional \$100 million to launch an intensive effort to control cancer, and that he would ask later for whatever additional funds could be effectively used.

December 23, 1971—The President signed P. L. 92-218, The National Cancer Act of 1971, providing increased authorities and responsibilities for the NCI Director; initiating a National Cancer Program; establishing a three-member President’s Cancer Panel and a 23-member National Cancer Advisory Board; establishing cancer control programs as necessary for cooperation with State and other health agencies, and providing for the collection, analysis, and dissemination of all data useful in the diagnosis, prevention, and treatment of cancer, including the establishment of an international cancer research data bank.

July 23, 1974—The National Cancer Act Amendments of 1974, P.L. 93-352, was signed. The Amendments: encourage the NCP to explore the role of nutrition in the treatment, rehabilitation, and causation of cancer; authorize the Director to include personnel needs in the budget estimate to OMB; remove the limit on the number of comprehensive cancer centers; increase the number of expert appointments to 100; and direct the NCI to provide and contract for a program to disseminate and interpret information respecting the cause, prevention, diagnosis and treatment of cancer.

August 1, 1977—The Biomedical Research Extension Act of 1977, P.L. 95-83, increased the number of expert appointments from 100 to 151.

November 9, 1978—The Biomedical Research and Training Amendments of 1978, P.L. 95-622, was signed into law, authorizing appropriations for fiscal years 1979 and 1980. The amendments redefined the National Cancer Program to highlight prevention activities; expanded the membership of the National Cancer Advisory Board to 29 members; added basic research to the cancer centers authority; authorized travel and moving expenses to and from duty station for experts; and emphasized education and information in all aspects of the National Cancer Program.

December 17, 1980—The Health Programs Extension Act of 1980, P.L. 96-538, was signed into law, authorizing expenditure of funds for fiscal years 1981 and 1982.

- August 5, 1937**—President Franklin D. Roosevelt signed the National Cancer Act.
- November 9, 1937**—The National Advisory Cancer Council held its first meeting.
- January 13, 1938**—Dr. Carl Voegtlin was appointed the first Director of the Institute.
- October 31, 1940**—President Franklin D. Roosevelt dedicated Building 6.
- July 1, 1947**—NCI reorganized to provide for expanded program; intramural cancer research, cancer research grants, and cancer control activities.
- July 2, 1953**—NCI inaugurated a full-scale clinical research program in the new Clinical Center.
- April 1955**—The Cancer Chemotherapy National Service Center was established in the Institute to coordinate the first national, voluntary, cooperative cancer chemotherapy program.
- January 11, 1966**—NCI reorganized to coordinate related activities. The areas of three Scientific Directors were established: Etiology; Chemotherapy; and a group of discipline-oriented laboratories and branches referred to as General Laboratories and Clinics.
- April 27, 1970**—At the request of Senator Ralph W. Yarborough, Chairman of the Committee on Labor and Public Welfare, the Senate approved the establishment of the National Panel of Consultants on the Conquest of Cancer.
- October 18, 1971**—President Nixon converted the Army's former biological warfare facilities at Fort Detrick, Md., to research on the causes, treatment and prevention of cancer.
- December 23, 1971**—President Nixon signed P.L. 92-218, The National Cancer Act of 1971.
- June 22, 1972**—The Institute awarded a contract for the operation and maintenance of the Frederick Cancer Research Center at Fort Detrick, Maryland. This constituted the largest research contract ever awarded by a research component of the National Institutes of Health.
- June 30, 1972**—A U. S.-U.S.S.R. agreement on the exchange of drugs, visiting scientists, and information was signed.
- July 27, 1972**—A Bureau-level organization was established for the National Cancer Institute, giving the Institute and its components organizational status commensurate with the responsibilities bestowed on it by The National Cancer Act of 1971. Under the reorganization, the Institute was composed of the Office of the Director and four Divisions.
- September 10, 1974**—NCI established the Division of Cancer Control and Rehabilitation.
- July 1975**—The Division of Cancer Treatment was expanded to include the NCI Surgery and Radiation Oncology Branches and the extramural program of Cancer Cooperative Clinical Trials.
- May 15, 1978**—The first phase of an extensive NCI reorganization was announced. Day-by-day administrative and funding responsibility for extramural research programs was consolidated in each of the four research divisions. Responsibility for grant and contract review committees and for other committee management activities was transferred to the Division of Cancer Research Resources and Centers.
- July 14, 1980**—The Division of Extramural Affairs replaced the Division of Cancer Research Resources and Centers. Also, the new Division of Resources, Centers and Community Activities replaced the Division of Cancer Control and Rehabilitation.
- July 14, 1981**—The NCI component of the National Toxicology Program was officially transferred to the National Institute of Environmental Health Sciences.
- September 26, 1982**—The single large contract for the operation of the Frederick Cancer Research Facility was recompeted as five separate contracts in FY 1982. A reorganization was implemented that centralized the management of Frederick under an Associate Director. The NCI Frederick Cancer Research Facility Advisory Committee was established to provide external peer review of the quality of the contractor-initiated research.
- October 2, 1983**—Official dedication of the R. A. Bloch International Cancer Information Center. This marked the integration of all components of NCI's information system, including the Institute's two journals, the International Cancer Research Data Bank, the Scientific Information Branch of the Division of Cancer Treatment, and the newly implemented PDQ system which provides the link to tie national clinical resources together and offers all cancer patients an equal opportunity for cure.
- November 30, 1983**—NCI retitled two Divisions to reflect more accurately their areas of emphasis following NCI reorganization. Division of Cancer Cause and Prevention became Division of Cancer Etiology; Division of Resources, Centers and Community Activities became Division of Cancer Prevention and Control.

**DIRECTOR
NATIONAL CANCER PROGRAM
NATIONAL CANCER INSTITUTE**

Vincent T. DeVita, Jr., M.D.

January 1, 1980 TO PRESENT

Dr. Vincent T. DeVita, Jr. received his B.S. degree from the College of William and Mary in 1957 and, in 1961, was awarded his M.D. degree with distinction from the George Washington University School of Medicine. He interned at the University of Michigan Medical Center and then completed a year of residency with the George Washington University medical service.

Dr. DeVita joined NCI in 1963 as a clinical associate and, after completing a senior residency at the Yale-New Haven Medical Center in 1966, returned to NCI as a senior investigator in the Solid Tumor Service. In 1971 he was appointed Chief of the Medicine Branch. In 1974 he was named Director of the Division of Cancer Treatment and, in 1975, Clinical Director of the Cancer Institute. In January 1980 he was named Director of the National Cancer Institute.

Dr. DeVita is a diplomate in the specialty of Internal Medicine and the subspecialties of Hematology and Medical Oncology. He serves on the editorial boards of many medical journals and maintains membership in many scientific and professional societies. He was President of the American Society of Clinical Oncology from 1977 to 1978. He has received many honors and awards for outstanding research and medical leadership: the 1972 Albert and Mary Lasker Medical Research Award, the Karnofsky Prize in 1979, the 1980 Griffuel Prize, the James Ewing Award in 1982. In addition he has received Honorary Doctor of Science degrees from the College of William and Mary in May 1982 and from Ohio State University in 1983, and Alumni Achievement Awards from the College of William and Mary in 1976 and the George Washington University in 1983.

PRESIDENT'S CANCER PANEL

	EXPIRATION OF APPOINTMENT
Armand Hammer, M.D., <i>Chairman 1983</i> Occidental International Corporation Washington, D. C.	1984
William P. Longmire, Jr., M.D. Center for Health Sciences University of California Los Angeles, California	1985
John A. Montgomery, Ph.D. Southern Research Institute Birmingham, Alabama	1986

EXECUTIVE SECRETARY

Elliott H. Stonehill, Ph.D.
National Cancer Institute
Bethesda, Maryland

NATIONAL CANCER ADVISORY BOARD

APPOINTEES

EXPIRATION OF
APPOINTMENT

Dr. Tim Lee Carter, <i>Chairman</i> Carter Clinic Tompkinsville, Kentucky	1988
Mr. Richard A. Bloch Kansas City, Missouri	1988
Dr. Roswell K. Boutwell University of Wisconsin Madison, Wisconsin	1984
Mrs. Angel Bradley North Miami, Florida	1988
Dr. Victor Braren Vanderbilt University School of Medicine Nashville, Tennessee	1988
Dr. Ed L. Calhoon Beaver, Oklahoma	1988
Dr. Maureen M. Henderson University of Washington Seattle, Washington	1984
Dr. Robert C. Hickey M.D. Anderson Hospital and Tumor Institute Houston, Texas	1986
Dr. Geza J. Jako Surgeon, Research Professor Melrose, Massachusetts	1988
Dr. Joseph Gale Katterhagen Tacoma General Hospital Tacoma, Washington	1986

EX OFFICIO MEMBERS

Dr. John F. Beary III Department of Defense Washington, D. C.
Dr. George A. Keyworth Office of Science and Technology Policy Washington, D. C.
Mr. William D. Ruckelshaus Environmental Protection Agency Washington, D. C.
Ms. Nancy Harvey Steorts Consumer Product Safety Commission Washington, D. C.
The Honorable Raymond J. Donovan Secretary of Labor Washington, D. C.
Dr. Donald L. Custis Veterans Administration Washington, D. C.

ALTERNATES TO EX OFFICIO MEMBERS

Dr. F. Kash Mostofi Armed Forces Institute of Pathology Washington, D. C.
Dr. Gordon Wallace Office of Science and Technology Policy Washington, D. C.
Dr. Elizabeth L. Anderson Environmental Protection Agency Washington, D. C.
Dr. Peter W. Preuss Consumer Product Safety Commission Bethesda, Maryland
Dr. Ralph E. Yodaiken Department of Labor Washington, D. C.

EXPIRATION OF
APPOINTMENT

Mrs. Rose Kushner Breast Cancer Advisory Center Kensington, Maryland	1986
Ann Landers Field Newspaper Syndicate Chicago, Illinois	1986
Dr. LaSalle D. Leffall Howard University Washington, D. C.	1986
Dr. William E. Powers Harper Grace Hospital Detroit, Michigan	1986
Dr. Janet D. Rowley University of Chicago Chicago, Illinois	1984
Mr. Sheldon W. Samuels AFL-CIO Washington, D. C.	1984
Mr. Morris M. Schrier MCA, Inc. New York, New York	1984
Dr. Irving J. Selikoff Mount Sinai School of Medicine New York, New York	1984


Dr. Mark Novitch Food and Drug Administration Rockville, Maryland
Dr. J. Donald Millar National Institute for Occupational Safety and Health Atlanta, Georgia
Dr. David P. Rall National Institutes of Environmental Health Sciences Research Triangle Park, North Carolina
The Honorable Margaret M. Heckler Secretary for Health and Human Services Washington, D. C.
Dr. James B. Wyngaarden National Institutes of Health Bethesda, Maryland

Dr. Hollis Boren Veterans Administration Washington, D. C.
Dr. Allen Heim Food and Drug Administration Rockville, Maryland
Dr. Elliott S. Harris National Institute for Occupational Safety and Health Atlanta, Georgia

EXECUTIVE SECRETARY

Mrs. Barbara S. Bynum National Cancer Institute, NIH Bethesda, Maryland


NATIONAL CANCER INSTITUTE




OFFICE OF THE DIRECTOR
 Dr. Vincent T. DeVita, Jr., Director
 Dr. Jane Henney, Deputy Director

Plans, develops, directs, and coordinates the activities and programs of the Institute and of the National Cancer Program; and provides overall policy guidance and staff direction.

EEO MANAGER
 Ms. Maxine I. Richardson





DIVISION OF CANCER TREATMENT
 Dr. Bruce Chabner, Director
 Dr. Saul A. Schepartz, Deputy Director

Plans, directs and coordinates an integrated program of cancer treatment activities with the objective of curing or controlling cancer in man by utilizing treatment modalities through intramural laboratory and clinical studies, contract, grant and cooperative agreement research, and research conducted in cooperation with other Federal agencies; administers targeted research and development programs in areas of drug development, biological response modifiers and radiotherapy development; administers a research program on all aspects of diagnostic imaging research and the biological effects of low-level exposures to ionizing radiation; and serves as the national focal point for information and data on experimental and clinical studies related to cancer treatment and for the distribution of such information to appropriate scientists and physicians.

BOARD OF SCIENTIFIC COUNSELORS
 Dr. Samuel Hellman, Chairman

ADMINISTRATIVE MANAGEMENT AND PLANNING BRANCH
 Mr. Michael Goldrich

CLINICAL ONCOLOGY PROGRAM
 Dr. Samuel Broder

RADIATION RESEARCH PROGRAM
 Dr. Francis J. Mahoney (acting)

BIOLOGICAL RESPONSE MODIFIERS PROGRAM
 Dr. Ronald B. Herberman (acting)

CANCER THERAPY EVALUATION PROGRAM
 Dr. Robert E. Wittes

DEVELOPMENTAL THERAPEUTICS PROGRAM
 Dr. J.A.R. Mead

MEDICINE BRANCH
 Dr. Robert C. Young

PEDIATRIC BRANCH
 Dr. Philip A. Pizzo

NCI-NAVY MEDICAL ONCOLOGY BRANCH
 Dr. John D. Minna

RADIATION ONCOLOGY BRANCH
 Dr. Eli J. Glatstein

SURGERY BRANCH
 Dr. Steven A. Rosenberg

RADIOTHERAPY DEVELOPMENT BRANCH
 Dr. Alfred R. Smith (acting)

DIAGNOSTIC IMAGING RESEARCH BRANCH
 Dr. Matti Al-Aish (acting)

LOW-LEVEL RADIATION EFFECTS BRANCH
 Dr. Bruce W. Wachholz

BIOLOGICAL THERAPEUTICS BRANCH
 Dr. Ronald B. Herberman

LABORATORY OF MOLECULAR IMMUNOREGULATION
 Dr. Joost J. Oppenheim

BIOLOGICAL RESOURCES BRANCH
 Dr. Richard V. Smalley

INVESTIGATIONAL DRUG BRANCH
 Dr. Daniel F. Hoth

CLINICAL INVESTIGATIONS BRANCH
 Dr. Michael A. Friedman

BIOMETRICS RESEARCH BRANCH
 Dr. Richard M. Simon

LABORATORY OF MEDICINAL CHEMISTRY AND BIOLOGY
 Dr. David G. Johns

LABORATORY OF MOLECULAR PHARMACOLOGY
 Dr. Kurt W. Kohn

LABORATORY OF CHEMICAL PHARMACOLOGY
 Dr. David G. Johns (acting)

LABORATORY OF TUMOR CELL BIOLOGY
 Dr. Robert C. Gallo

LABORATORY OF EXPERIMENTAL THERAPEUTICS AND METABOLISM
 Dr. Michael R. Boyd

**CLINICAL PHARMACOLOGY
BRANCH**

Dr. Charles E. Myers

**ANIMAL GENETICS AND
PRODUCTION BRANCH**

Dr. Joseph G. Mayo

**DRUG SYNTHESIS AND
CHEMISTRY BRANCH**

Dr. Ven Narayanan

**NATURAL PRODUCTS
BRANCH**

Dr. Matthew Suffness

**DRUG EVALUATION
BRANCH**

Dr. John M. Venditti

**PHARMACEUTICAL
RESOURCES BRANCH**

Mr. J. Paul Davignon

TOXICOLOGY BRANCH


Dr. Charles K. Grieshaber

**INFORMATION TECHNOLOGY
BRANCH**

Dr. G.W.A. Milne

**EXTRAMURAL RESEARCH
& RESOURCES BRANCH**

Dr. Moreshwar Nadkarni



DIVISION OF CANCER PREVENTION AND CONTROL

Dr. Peter Greenwald, Director
Dr. Joseph Cullen, Deputy Director

Plans and conducts basic and applied research and development, technology transfer, demonstration, education and information dissemination programs to expedite the use of new information relevant to the prevention, detection, and diagnosis of cancer and the pretreatment evaluation, treatment, rehabilitation, and the continuing care of cancer patients throughout the country; plans, directs, and coordinates the support of research on cancer prevention and control at cancer centers, community hospitals, and through organ systems programs; supports cancer research training, clinical education, continuing education and career development in cancer prevention and control; administers programs for the support of construction, alteration, renovation, and equipping of extramural research facilities; and coordinates program activities with other divisions, institutes, or federal and state agencies and establishes liaison with professional and voluntary health agencies, cancer centers, labor organizations, cancer organizations, and trade associations.

**ADMINISTRATIVE
MANAGEMENT AND
PLANNING BRANCH**
Mr. Nicholas Olimpio

**BOARD OF
SCIENTIFIC COUNSELORS**
**Dr. Lester Breslow,
Chairman**

**OPERATIONS RESEARCH
BRANCH**
Dr. Edward Sondik

BIOMETRY BRANCH
Dr. Earl Pollack

PREVENTION PROGRAM
Dr. William DeWys (acting)

**CENTERS AND COMMUNITY
ONCOLOGY PROGRAM**
Dr. Jerome Yates

**CANCER CONTROL
SCIENCE PROGRAM**
Dr. Joseph Cullen (acting)

**CANCER PREVENTION
STUDIES BRANCH**
**Dr. William DeWys
(acting)**

**DIET AND CANCER
BRANCH**
**Dr. Ritva Butrum
(acting)**

**COMMUNITY ONCOLOGY
AND REHABILITATION
BRANCH**
Dr. Jerome Yates (acting)

**CANCER CENTERS
BRANCH**
**Dr. Jerome Yates
(acting)**

**CANCER TRAINING
BRANCH**
Dr. Barney C. Lepovetsky

**OCCUPATIONAL CANCER
BRANCH**
**Dr. Veronica Conley
(acting)**

**CANCER DETECTION
BRANCH**
Dr. Richard Costlow

**ORGAN SYSTEMS
BRANCH**
Dr. Andrew Chiarodo

**RESEARCH FACILITIES
BRANCH**
Dr. Donald Fox

**CANCER CONTROL
APPLICATIONS BRANCH**
**Mr. Thomas Kean
(acting)**


**CHEMOPREVENTION
BRANCH**
**Dr. Winfred Malone
(acting)**

**HEALTH PROMOTION
SCIENCES BRANCH**
**Dr. Lillian Gigliotti
(acting)**

DIVISION OF EXTRAMURAL ACTIVITIES


Mrs. Barbara S. Bynum, Director

Administers and directs the Institute's grant and contract review and processing activities; provides initial technical and scientific merit review of grants and contracts for the Institute; represents the Institute on over-all NIH extramural and collaborative program policy committees, coordinates such policy within NCI, and develops and recommends NCI policies and procedures as related to the review of grants and contracts; coordinates the Institute's review of research grant and training programs with the National Cancer Advisory Board; coordinates the implementation of committee management policies within the Institute and provides the Institute's staff support for the National Cancer Advisory Board; coordinates program planning and evaluation in the extramural area; provides scientific reports and analyses to the Institute's grant and contract programs; coordinates and administers the Institute's participation in minority research and training efforts.



5-YEAR RELATIVE SURVIVAL RATES

By Primary Site for Patients (all races, both sexes) Diagnosed 1973-1980,
National Cancer Institute SEER Program



NUMBER OF DEATHS FOR THE FIVE LEADING CANCER SITES BY AGE GROUP AND SEX — 1980

TOTAL		UNDER 15		15-34		35-54		55-74		75+	
MALE	FEMALE	MALE	FEMALE	MALE	FEMALE	MALE	FEMALE	MALE	FEMALE	MALE	FEMALE
Lung 75,421	Breast 35,640	Leukemia 536	Leukemia 338	Leukemia 840	Breast 628	Lung 9,842	Breast 8,012	Lung 48,914	Breast 18,214	Lung 16,495	Colon & Rectum 13,158
Colon & Rectum 26,665	Lung 28,252	Brain & CNS 255	Brain & CNS 203	Brain & CNS 494	Leukemia 594	Colon & Rectum 2,323	Lung 4,819	Colon & Rectum 14,244	Lung 17,336	Prostate 13,080	Breast 8,784
Prostate 22,880	Colon & Rectum 28,016	Endo- crine 138	Endo- crine 88	Non- Hodgkin's Lympho- mas 375	Brain & CNS 309	Pancreas 1,253	Colon & Rectum 2,130	Prostate 9,470	Colon & Rectum 12,545	Colon & Rectum 9,902	Lung 5,999
Pancreas 10,994	Uterus 10,908	Non- Hodgkin's Lympho- mas 106	Bone 58	Testis 302	Uterus 306	Brain & CNS 1,188	Uterus 1,926	Pancreas 6,512	Ovary 5,887	Bladder 3,232	Pancreas 4,289
Leukemia 9,306	Ovary 10,731	Connective Tissue 57	Kidney 42	Hodgkin's Disease 300	Hodgkin's Disease 206	Leukemia 1,134	Ovary 1,866	Stomach 4,613	Uterus 5,534	Pancreas 3,190	Uterus 31,40

Source: Vital Statistics of the United States, 1980.

RELATIONSHIP OF CANCER TO LEADING CAUSES OF DEATH IN THE UNITED STATES — 1980

RANK	CAUSE OF DEATH	NUMBER OF DEATHS	DEATH RATE PER 100,000 POPULATION	PERCENT OF TOTAL DEATHS
	All Causes	1,989,841	878.3	100.0
1	Diseases of Heart	761,085	336.0	38.3
2	Cancer	416,509	183.9	20.9
3	Stroke	170,225	75.1	8.6
4	Accidents	105,718	46.7	5.3
5	Bronchitis, Emphysema & Asthma	56,050	24.7	2.8
6	Pneumonia and Influenza	54,619	24.1	2.7
7	Diabetes Mellitus	34,851	15.4	1.8
8	Cirrhosis of Liver	30,583	13.5	1.5
9	Arteriosclerosis	29,449	13.0	1.5
10	Suicide	26,869	11.9	1.4
11	Homicide	24,278	10.7	1.2
12	Diseases of Infancy	22,866	10.1	1.1
13	Nephritis and Nephrosis	16,753	7.4	0.8
14	Congenital Abnormalities	13,938	6.2	0.7
15	Septicemia and Pyemia	9,438	4.2	0.5
	Other and Ill-defined	216,610	95.4	10.9

Source: National Center for Health Statistics, 1980.

ESTIMATED CANCER DEATHS AND NEW CASES BY SEX AND SITE—1983¹

SITE	ESTIMATED DEATHS			ESTIMATED NEW CASES		
	TOTAL	MALE	FEMALE	TOTAL	MALE	FEMALE
All Sites	440,000	238,500	201,500	855,000 ¹	422,500 ¹	432,500 ¹
Buccal Cavity & Pharynx (Oral)	9,150	6,300	2,850	27,100	18,600	8,500
Lip	175	150	25	4,600	4,100	500
Tongue	2,000	1,400	600	4,900	3,200	1,700
Salivary Gland	700	450	250	9,800	5,800	4,000
Floor of Mouth	525	400	125			
Other & Unspecified Mouth	1,550	1,000	550			
Pharynx	4,200	2,900	1,300	7,800	5,500	2,300
Digestive Organs	115,200	60,250	54,950	202,400	103,700	98,700
Esophagus	8,500	6,200	2,300	9,000	6,400	2,600
Stomach	13,900	8,200	5,700	24,500	14,800	9,700
Small Intestine	700	350	350	2,100	1,100	1,000
Large Intestine } (Colon- Rectum } Rectum)	49,600	23,500	26,100	87,000	40,000	47,000
Rectum	8,500	4,600	3,900	39,000	21,000	18,000
Liver & Biliary Passages	10,000	4,900	5,100	13,300	6,300	7,000
Pancreas	22,600	11,800	10,800	25,000	12,900	12,100
Other & Unspecified Digestive	1,400	700	700	2,500	1,200	1,300
Respiratory System	122,100	87,000	35,100	149,100	105,200	43,900
Larynx	3,700	3,100	600	11,000	9,200	1,800
Lung	117,000	83,000	34,000	135,000	94,000	41,000
Other & Unspecified Respiratory	1,400	900	500	3,100	2,000	1,100
Bone, Tissue & Skin	10,500	6,000	4,500	24,100	12,200	11,900
Bone	1,750	1,000	750	1,900	1,100	800
Connective Tissue	1,650	800	850	4,800	2,600	2,200
Skin	7,100 ⁴	4,200	2,900	17,400 ²	8,500 ²	8,900 ²
Breast, Invasive	37,500	300	37,200	114,900 ³	900 ³	114,000 ³
Genital Organs	47,550	25,050	22,500	158,000	80,400	77,600
Cervix, Invasive } Uterus	7,000	—	7,000	16,000 ³	—	16,000 ³
Corpus, Endometrium }	3,000	—	3,000	39,000	—	39,000
Ovary	11,500	—	11,500	18,200	—	18,200
Prostate	24,100	24,100	—	75,000	75,000	—
Other & Unspecified Genital, Male	950	950	—	5,400	5,400	—
Other & Unspecified Genital, Female	1,000	—	1,000	4,400	—	4,400
Urinary Organs	19,200	12,500	6,700	56,700	39,400	17,300
Bladder	10,700	7,300	3,400	38,500	28,000	10,500
Kidney & Other Urinary	8,500	5,200	3,300	18,200	11,400	6,800
Eye	400	200	200	1,800	900	900
Brain & Central Nervous System	10,800	5,900	4,900	12,600	7,000	5,600
Endocrine Glands	1,500	600	900	11,200	3,500	7,700
Thyroid	1,050	350	700	10,200	2,900	7,300
Other Endocrine	450	250	200	1,000	600	400
Leukemia	16,100	9,000	7,100	23,900	13,200	10,700
Other Blood & Lymph Tissues	20,800	10,700	10,100	40,300	21,000	19,300
Hodgkin's Disease	1,600	900	700	7,100	4,100	3,000
Multiple Myeloma	6,900	3,500	3,400	9,600	4,900	4,700
Other Lymphomas	12,300	6,300	6,000	23,600	12,000	11,600
All Other & Unspecified Sites	29,200	14,700	14,500	32,900	16,500	16,400

Note: The estimates of new cancer cases are offered as a rough guide and should not be regarded as definitive. Especially note that year-to-year changes may only represent improvements in the basic data.

¹Carcinoma in situ and non-melanoma skin cancers not included in totals. Carcinoma in situ of the uterine cervix accounts for over 45,000 new cases annually and carcinoma in situ of the female breast accounts for over 5,000 new cases annually. Non-melanoma skin cancer accounts for about 400,000 new cases annually. ²Melanoma only. ³Invasive cancer only. ⁴Melanoma 5,200; other Skin 1,900.

Incidence estimates are based on rates from NCI SEER Program, 1973-1979.

RESEARCH POSITIONS AT THE NATIONAL CANCER INSTITUTE¹

The National Cancer Institute recognizes that one of the most valuable resources to be drawn upon in the fight against cancer is the wealth of scientific talent available in the U. S. and around the world. In an effort to attract and maintain the highest quality scientific staff, two personnel systems are used: the U. S. Civil Service System and the PHS Commissioned Corps. In addition, the Staff Fellowship Program and the NIH Visiting Program have been designed to meet special needs. Special programs are also available for those who qualify.

POSITION	ELIGIBILITY	ANNUAL SALARY	MECHANISM OF ENTRY
I. CIVIL SERVICE			
A. Civil Service (tenured)	Appropriate advanced education, experience and knowledge needed by NCI to conduct its programs.	Minimum starting: Ph.D. — \$34,930 Physicians — \$49,533 Maximum: \$63,800	Office of Personnel Management, Contact Director or Laboratory Chief in area of interest or the NCI Personnel Office.
II. SPECIAL APPOINTMENT OF EXPERTS AND CONSULTANTS			
A. Special Appointment of Experts and Consultants (non-tenured appointment which can be extended up to 4 years).	Applicants shall possess outstanding experience and ability as to justify recognition as authorities in their particular fields of activity.	Equivalent to the salary range of GS-13 through GS-18. Maximum: \$63,800	Recommendation by Division Directors. Final approval rests with the Director, NCI.
III. MEDICAL STAFF FELLOWS			
A. Medical Staff Fellows	Appointment for 2 or 3 years with an additional 1-year extension for an initial 2-year appointment. Graduate of accredited medical or osteopathic school and completion of internship. Completion of 2 or 3 years of clinical training beyond the M.D. degree and demonstrated outstanding ability to conduct successfully, preestablished programs in both clinical and laboratory research.	\$30,000-\$34,000	Apply to the Clinical and Professional Education Section, Clinical Center, National Institutes of Health 20205.
B. Medical Staff Fellows in Pharmacology (PRAT Fellows). For physicians committed to research careers in pharmacological sciences, or clinical pharmacology.	Appointment for 2 or 3 years with an additional 1-year extension for an initial 2-year appointment. Graduate of accredited medical or osteopathic school and completion of internship. Completion of 2 or 3 years of clinical training beyond the M.D. degree and demonstrated outstanding ability to conduct successfully, preestablished programs in both clinical and laboratory research.	\$30,000-\$34,000	Apply to the Clinical and Professional Education Section, Clinical Center, National Institutes of Health 20205.
IV. VISITING PROGRAM (limited tenure)²			
A. Visiting Fellow (maximum 3 years)	1-3 years postdoctoral experience or training.	Entrance stipend \$16,000-\$17,600 No dependency allowance provided.	Contact Director or Laboratory Chief in area of interest.
B. Visiting Associates (1 year with renewals to end of project)	3+ years postdoctoral experience or training with appropriate knowledge needed by NCI.	\$20,256-\$38,185	Contact Director or Laboratory Chief in area of interest.
C. Visiting Scientist (duration of project)	6+ years postdoctoral experience with appropriate unusual experience and knowledge needed.	\$29,374-\$63,800	Contact Director or Laboratory Chief in area of interest.

¹ Does not necessarily indicate that positions are currently available at the National Cancer Institute.

² Under most circumstances, the various visiting programs are limited to non-citizens.

V. STAFF FELLOWSHIPS

POSITION	ELIGIBILITY	ANNUAL SALARY	MECHANISM OF ENTRY
A. Staff Fellowship	Physician or other doctoral degree equivalent awarded within last 5 years, U.S. citizen or non-citizen eligible for naturalization within 4 years. Maximum seven-year appointment.	Staff Fellows Physicians \$20,688-\$34,312 Other Doctorates \$17,000-\$34,269 Senior Staff Fellows Physicians \$23,439-\$46,570 Other Doctorates \$20,688-\$38,422	Contact Director or Laboratory Chief in area of interest or the NCI Personnel Office.


VI. CIVIL SERVICE SUMMER EMPLOYMENT PROGRAMS


A. Summer Clerical Program	Must be 18 years of age or older (16 if high school graduate).	GS-1 through GS-4 Grade is based on education and/or experience.	Apply to NIH on or before March 15.
B. Summer Undergraduate Program	Students majoring in biological and/or physical sciences or related field, or applicants with appropriate experience.	GS-1 through GS-4 Grade is based on education and/or experience.	Apply to NIH by March 15.
C. Summer Graduate Program	College graduate, graduate student, planning to attend graduate school, faculty member, or equivalent experience and/or education.	GS-5 through GS-12 For some occupations superior scholastic work may qualify for a higher grade level.	Apply to NIH by March 15.
D. Summer Employment for Needy Youth	Educationally and economically disadvantaged youths in their formative years (must have reached 16th birthday).	Federal minimum wage.	Register with the local office of the State Employment service and apply to NIH.
E. Stay-in-School Program	Substantially full-time or full-time student at least 16 years of age who needs earnings from employment to continue in school.	Salary is commensurate with duties assigned and student's education and/or experience.	Apply to NIH. No deadline required for applying. However, no new appointments are made between May 1 to August 30.
F. The Federal Junior Fellowship Program	Graduating high school senior in a public or private school in the Metro. Wash., D. C. area. Must be in upper 10% of graduating class, have applied for admission to an accredited college or university and need financial assistance to attend school.	GS-1 through GS-4	Nominations are submitted directly to the Office of Personnel Management by high school principals or counselors.

VII. SPECIAL PROGRAMS

A. Research Fellow sponsored by organization other than NIH, PHS.	Determined by sponsoring organization.	Established by sponsoring organization.	Contact Director or Laboratory Chief in area of interest; also apply to sponsoring agency, e.g., American Cancer Society, Eleanor Roosevelt Cancer Foundation, Leukemia Society of America, Inc., etc.
B. COSTEP Program (operates year-round) Maximum 120 days per 12-month period.	U.S. Citizen. Must have completed one year of study in a medical, dental or veterinary school; or a minimum of two years of baccalaureate program in a health-related field such as engineering, nursing, pharmacy, etc. May be enrolled in a master's or doctoral program in a health-related field (designated by the Assistant Secretary for Health). Physical requirements of PHS Commissioned Corps. Plans to return to college.	Pay and allowance of a Commissioned Officer, Junior Asst. Grade.	Apply to PHS Commissioned Corps, COSTEP SECTION, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20852.
C. Fogarty International Scholars In Residence Program.	International reputation, productivity, demonstrated ability in biomedical field.	\$60,000 for 10 months	Recommendation to Fogarty Center by Institute Director or Scientist. Contact Director in area of interest.

NCI INTRAMURAL REVIEW PROCESS





BUILDING 82
 R. A. Bloch
 International
 Cancer Information
 Center
 16,000 Square Feet
 32 Personnel

BUILDING 10
 CLINICAL CENTER
 96,492 Square Feet
 364 Personnel

BUILDING 37
 117,249 Square Feet
 392 Personnel

BUILDING 36
 3,131 Square Feet
 18 Personnel

BUILDING 14
 4,716 Square Feet
 4 Personnel

BUILDING 31
 40,458 Square Feet
 198 Personnel

BUILDING 41
 31,353 Square Feet
 57 Personnel

LANDOW BUILDING
 47,341 Square Feet
 256 Personnel

WESTWOOD BUILDING
 30,862 Square Feet
 111 Personnel

***INCLUDED BUT NOT SHOWN**
 FIELD STATIONS
 18,616 Square Feet †
 109 Personnel
 BLAIR BUILDING
 8300 Colesville Road
 Silver Spring, MD
 20910
 47,566 Square Feet
 190 Personnel

†Excludes Frederick
 Cancer Research Facility.

**BUILDING LOCATION AND
 SQUARE FOOTAGE OCCUPIED
 BY FULL-TIME PERMANENT
 PERSONNEL IN BETHESDA,
 MARYLAND AREA
 AS OF SEPTEMBER 30, 1983**

TOTAL*
 Approximately 453,784 Square Feet
 1,731 Personnel

MAJOR STEPS IN THE BUDGET FORMULATION REVIEW PROCESS

	JANUARY	FEBRUARY	MARCH	APRIL	MAY	JUNE	JULY	AUGUST	SEPTEMBER	OCTOBER	NOVEMBER	DECEMBER
NCI STAFF ¹	NCI Director's Meeting—establish budget policy for upcoming fiscal year; review operating plans for current fiscal year Submit Congressional Justification for next fiscal year		Formulation of Preliminary Budget for two years in the future for both the by-pass, and budget submitted within the Administration's guidelines Congressional Testimony by Director, NCI			NCI Director's Meeting—establish specific division levels for upcoming fiscal year		Formulation of By-Pass Budget Formulation of Budget within Administration guidelines		Formulation of President's Budget		
NCAB ²						Review and revise Preliminary Budget for two fiscal years in future		Review By-Pass (OMB) Budget submitted directly to the President		Division presentations of program activities for fiscal year just completed		
BSC ³	Review operating plans for current fiscal year and policies from NCI Director's Meeting					Review and advise on implementation of specific divisional programs current fiscal year				Annual Division Budget Reviews current and future plans		


¹ Executive Committee and key administrative staff

² National Cancer Advisory Board—presidential appointees

³ Board of Scientific Counselors—outside NCI peer review bodies for each of four operating divisions

ESTIMATED TOTAL NATIONAL RESOURCES FOR CANCER RESEARCH AND CANCER CONTROL — FISCAL YEAR 1983


TOTAL \$1,995,249,000




NOTE: Non-NCI resources data were provided by the Office of Program Planning and Analysis, NCI.

NCI PROGRAM STRUCTURE—FISCAL YEAR 1983

TOTAL DOLLARS
\$986,811,000



NATIONAL CANCER INSTITUTE BUDGET HISTORY BY GROUP




NATIONAL CANCER INSTITUTE BUDGET HISTORY BY MECHANISMS

(DOLLARS IN THOUSANDS)

	1974 ACTUAL		1975 ACTUAL		1976 ACTUAL		1977 ACTUAL	
	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL
Group I—Investigator Initiated								
Regular Research Grants	\$ 99,415	21.5	\$115,195	21.4	\$130,633	22.7	\$140,159	23.0
Clinical Cooperative Groups	16,196	3.5	19,213	3.6	23,263	4.0	27,121	4.5
Program Projects—POI's	71,997	15.6	84,536	15.7	80,029	13.9	83,453	13.7
Clinical Education Program	—	—	5,033	.9	7,698	1.3	8,996	1.5
Research Career Program	1,673	.4	2,806	.5	3,243	.6	3,507	.6
Fellowships and Training	23,562	5.1	23,104	4.3	18,160	3.1	19,791	3.3
Organ Site	10,007	2.2	11,167	2.1	14,090	2.5	14,711	2.4
Cancer Centers—Core Support	17,575	3.8	30,096	5.6	47,803	8.3	55,132	9.1
Other Centers—Support Grants	—	—	—	—	—	—	—	—
Cooperative Agreements	—	—	—	—	—	—	—	—
Minority Biomedical Support	—	—	—	—	—	—	—	—
Organ Systems	—	—	—	—	—	—	—	—
Subtotal	240,425	52.1	291,150	54.1	324,919	56.4	352,870	58.1
Group II—Co-Initiated								
CREG/RFA	—	—	—	—	2,577	.5	7,266	1.2
Research Contracts	94,964	20.5	105,076	19.5	111,524	19.3	110,740	18.2
Subtotal	94,964	20.5	105,076	19.5	114,101	19.8	118,006	19.4
Group III—NCI/NCP Initiated								
Resource Contracts	72,365	15.7	82,916	15.4	96,509	16.7	94,229	15.5
Interagency Agreements	13,031	2.8	11,593	2.2	13,262	2.3	19,414	3.2
Subtotal	85,396	18.5	94,509	17.6	109,771	19.0	113,643	18.7
Group IV—Other Resources								
Planning Grants	2,880	.6	2,568	.4	2,803	.5	1,199	.2
Construction Grants	31,692	6.9	30,000	5.6	20,000	3.5	16,000	2.6
Construction Contracts	6,398	1.4	14,976	2.8	4,721	.8	5,992	1.0
Subtotal	40,970	8.9	47,544	8.8	27,524	4.8	23,191	3.8
Total	461,755	100.0	538,279	100.0	576,315	100.0	607,710	100.0
Percent of Total NCI Budget		79.5		77.0		75.7		74.6
In-House Research	40,364	6.9	50,532	7.2	61,243	8.0	67,855	8.3
Management & Support	46,169	7.9	61,935	8.9	69,876	9.2	80,184	9.8
(NIH Management Fund)	(16,754)	(2.9)	(20,248)	(2.9)	(23,037)	(3.0)	(26,817)	(3.3)
Cancer Control (Grants & Contracts)	32,826	5.7	48,574	6.9	54,016	7.1	59,208	7.3
Subtotal	119,359	20.5	161,041	23.0	185,135	24.3	207,247	25.4
Total NCI	\$581,114	100.0	\$699,320	100.0	\$761,450	100.0	\$814,957	100.0

1978 ACTUAL		1979 ACTUAL		1980 ACTUAL		1981 ACTUAL		1982 ACTUAL		1983 ACTUAL	
DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL
\$158,716	24.7	\$188,488	27.3	\$213,610	29.0	\$237,662	32.6	\$240,956	33.8	\$276,872	39.2
29,774	4.6	32,021	4.6	36,884	5.0	35,094	4.8	38,808	5.5	44,704	6.3
88,058	13.7	93,953	13.6	104,094	14.1	115,311	15.8	111,365	15.6	116,059	16.4
9,952	1.5	11,404	1.7	10,906	1.5	7,999	1.1	4,614	0.6	4,984	0.7
4,399	.7	4,771	0.7	5,357	0.7	5,480	0.8	5,706	0.8	5,215	0.7
20,129	3.1	20,139	2.9	27,260	3.7	25,606	3.5	22,374	3.1	23,953	3.4
16,194	2.5	17,032	2.5	17,554	2.4	15,962	2.2	13,945	2.0	-	-
60,348	9.4	64,364	9.3	67,421	9.1	71,408	9.8	70,977	10.0	77,372	11.0
-	-	-	-	-	-	-	-	4,019	0.6	-	-
-	-	-	-	800	0.1	300	-	504	0.1	4,024	0.6
-	-	-	-	1,980	0.3	1,727	0.2	1,977	0.3	2,087	0.3
-	-	-	-	-	-	-	-	-	-	591	0.1
387,570	60.2	432,172	62.6	485,866	65.9	516,549	70.8	515,245	72.4	555,861	78.7
9,412	1.5	7,894	1.1	6,971	0.9	6,712	0.9	9,403	1.3	12,625	1.8
120,359	18.6	81,119	11.8	57,446	7.8	43,928	6.0	33,664	4.7	36,119	5.1
129,771	20.1	89,013	12.9	64,417	8.7	50,640	6.9	43,067	6.0	48,744	6.9
87,806	13.6	130,161	18.9	151,305	20.5	140,622	19.3	88,028	12.4	85,069	12.1
21,621	3.4	20,734	3.0	20,615	2.8	16,881	2.3	61,404	8.6	13,710	1.9
109,427	17.0	150,895	21.9	171,920	23.3	157,503	21.6	149,432	21.0	98,779	14.0
632	.1	271	.1	221	-	-	-	-	-	-	-
12,000	1.9	12,452	1.8	10,814	1.5	2,027	.3	1,225	0.2	1,500	0.2
4,544	.7	4,878	.7	4,618	.6	3,200	.4	3,268	0.4	1,500	0.2
17,176	2.7	17,601	2.6	15,653	2.1	5,227	.7	4,493	0.6	3,000	0.4
643,944	100.0	689,681	100.0	737,856	100.0	729,919	100.0	712,237	100.0	706,384	100.0
	73.8		73.6		73.9		73.8		72.2		71.6
79,217	9.1	88,944	9.5	98,665	9.9	109,377	11.0	112,125	11.4	115,534	11.7
86,594	9.9	91,167	9.7	97,863	9.8	96,495	9.8	110,012	11.1	116,132	11.8
(30,150)	(3.5)	(35,622)	(3.8)	(39,549)	(4.0)	(42,471)	(4.3)	(48,817)	(4.9)	(49,632)	(5.0)
62,614	7.2	66,904	7.2	63,663	6.4	53,547	5.4	52,190	5.3	48,761	4.9
228,425	26.2	247,015	26.4	260,191	26.1	259,419	26.2	274,327	27.8	280,427	28.4
\$872,369	100.0	\$936,696	100.0	\$998,047	100.0	\$989,338	100.0	\$986,564	100.0	\$986,811	100.0


NCI RESEARCH PROGRAMS — FISCAL YEAR 1983



Research Programs	Amount	PERCENT OF TOTAL
Research Programs	\$811,455,000	82.2
Resource Development		
Cancer Centers Support	78,748,000	8.0
Research Manpower Development	36,527,000	3.7
Construction	3,470,000	0.4
Cancer Control	56,611,000	5.7
Total NCI	\$986,811,000	100.0

NCI EXTRAMURAL FUNDS — FISCAL YEAR 1983

Total Extramural
\$755,145,000




TOTAL NCI DOLLARS BY MECHANISMS — FISCAL YEAR 1983

(DOLLARS IN THOUSANDS)


	AMOUNT	MECHANISM	PERCENT OF TOTAL	
	RESEARCH PROJECT GRANTS			
\$406,143	\$265,790	Traditional (RO1)	26.9	41.2%
	5,406	Young Investigators	0.5	
	12,625	Cancer Research Emphasis Grants/RFA's	1.3	
	116,059	Program Projects	11.8	
	4,769	Cooperative Agreements	0.5	
	1,494	Small Business Innovative Research	0.2	
	RESEARCH CENTERS GRANTS			
\$77,372	1,307	Other Centers	0.1	7.8%
	76,065	Center Core Grants	7.7	
	OTHER RESEARCH GRANTS			
\$60,795	2,850	Scientific Evaluation	0.3	6.2%
	587	Conference Grants	0.1	
	4,992	Research Career Programs	0.5	
	4,984	Clinical Education Programs	0.5	
	44,704	Clinical Cooperative Groups	4.5	
	591	National Organ Systems Program	0.1	
	2,087	Minority Biomedical Research Support	0.2	
	TRAINING PROGRAM			
\$23,953	3,009	National Research Service Awards—Individual	0.3	2.4%
	20,944	National Research Service Awards—Institutional	2.1	
	RESEARCH AND RESOURCE CONTRACTS			
\$134,898	134,898	Research and Resource Contracts	13.7	13.7%
	CANCER CONTROL			
\$53,569	53,569	Cancer Control	5.4	5.4%
	CONSTRUCTION			
\$3,000	3,000	Construction	0.3	0.3%
	IN-HOUSE			
\$227,081	174,000	Intramural Research	17.6	23.0%
	41,088	Direct Operations	4.2	
	11,993	Program Management	1.2	
	\$986,811	TOTAL NCI	100.0	

CANCER CONTROL OBLIGATIONS BY MECHANISM — FISCAL YEARS 1974-1983



REIMBURSEMENT TO NIH MANAGEMENT FUND—FISCAL YEAR 1983


TOTAL NIH SERVICES
\$201,204,000



- CLINICAL CENTER**
- Employee Health Services
 - Service Functions
 - Social Work
 - Professional Services
 - Consultative Services
 - Admissions and Follow-up
 - Anesthesiology
 - Diagnostic X-Ray
 - Clinical Pathology
 - Blood Bank
 - Rehabilitation Service
 - Pharmacy Service
 - Medical Records
 - TV Engineering
 - Nursing Service
 - Patient Nutrition Service
 - Environmental Sanitation Control
 - Laundry
 - Radiation Safety

- STANDARD LEVEL USER CHARGES (SLUC)**
- Building usage including utilities
 - Major renovations
 - Guard services for rental buildings

DISTRIBUTION OF NCI SERVICES
\$49,632,000



DIVISION OF COMPUTER RESEARCH AND TECHNOLOGY

Research & Development Program in Which Concepts & Methods of Computer Science Are Applied to Bio-medical Problems (In addition, services are rendered to the NIH Communities on a fee-for-service basis.)

DIVISION OF RESEARCH GRANTS


- Initial Scientific Review of Applications
- Assignment of Research Grant Applications Among Institutes

OTHER RESEARCH SERVICES


- Division of Administrative Services
- Division of Engineering Services
- Division of Safety
- Division of Research Services

The Management Fund provides for the financing of certain common research supporting services and administrative activities which are required in the operating of NIH.

NCI GRANT PROCESS



NCI CONTRACT AWARD PROCESS — UNDER CANCER ACT OF 1971



NOTE: SIMULTANEOUS ACTIVITIES BY MORE THAN ONE ORGANIZATION INDICATE COOPERATIVE EFFORTS.


LEGEND:

- OPERATION
- REVIEW
- ▲ DECISION

- NORMAL COMPETITIVE FLOW
- - - - NON-COMPETITIVE CONTRACTS
- * AD HOC COMMITTEES MAY BE USED — INCLUDES NON-GOVERNMENT EMPLOYEES.

STATE DISTRIBUTION OF GRANTS AND CONTRACTS — FISCAL YEAR 1983


(DOLLARS IN THOUSANDS)



NOTE: Contract figures exclude Foreign Contracts: \$2,863; Grant figures exclude Foreign Grants: \$4,327; and Scientific Evaluation: \$2,850.

DISTRIBUTION OF CANCER CONTROL GRANTS AND CONTRACTS — FISCAL YEAR 1983

(DOLLARS IN THOUSANDS)



INSTITUTIONS RECEIVING MORE THAN \$2,000,000 FROM THE NATIONAL CANCER INSTITUTE IN FISCAL YEAR 1983

(DOLLARS IN THOUSANDS)

NAME OF INSTITUTION	GRANTS	CONTRACTS	CONSTRUCTION	TOTAL	STATE
University of Alabama System	\$ 8,457	\$ 350	\$ -	\$ 8,807	Alabama
Southern Research Institute	2,390	2,234	-	4,624	Alabama
University of Arizona	5,705	886	-	6,591	Arizona
University of California	42,107	1,952	200	44,259	California
Stanford University	11,621	137	-	11,758	California
University of Southern California	9,095	2,629	-	11,724	California
Litton Industries	-	11,199	-	11,199	California
Scripps Clinic and Research Foundation	4,921	-	-	4,921	California
Northern California Cancer Program, Inc.	1,677	2,686	-	4,363	California
Salk Institute for Biological Studies	4,170	-	-	4,170	California
SRI International	1,434	2,677	-	4,111	California
La Jolla Cancer Research Foundation	2,737	-	-	2,737	California
University of Colorado System	2,813	-	-	2,813	Colorado
Colorado State University	2,192	-	-	2,192	Colorado
Yale University	13,733	558	-	14,291	Connecticut
U. S. Department of the Army	140	4,940	-	5,080	Dist. of Col.
U. S. Department of Health and Human Services	198	2,569	-	2,767	Dist. of Col.
Georgetown University	2,004	664	-	2,668	Dist. of Col.
U. S. Department of Energy	-	2,620	-	2,620	Dist. of Col.
George Washington University	2,353	-	-	2,353	Dist. of Col.
University of Miami	3,366	556	-	3,922	Florida
State University System of Florida	3,122	5	-	3,127	Florida
Emory University	1,923	860	-	2,783	Georgia
University of Hawaii System	1,685	679	-	2,364	Hawaii
University of Chicago	9,021	91	-	9,112	Illinois
American College of Radiology	2,941	526	-	3,467	Illinois
University of Illinois	3,346	106	-	3,452	Illinois
Northwestern University	3,261	91	-	3,352	Illinois
IIT Research Institute	161	2,125	-	2,286	Illinois
Illinois Cancer Council	1,625	485	-	2,110	Illinois
University of Iowa	2,684	1,998	-	4,682	Iowa
Jackson Laboratory	2,033	-	-	2,033	Maine
Program Resources, Inc.	-	21,349	752	22,101	Maryland
Johns Hopkins University	14,195	1,047	-	15,242	Maryland
Westat, Inc.	-	4,877	-	4,877	Maryland
University of Maryland System	2,245	809	-	3,054	Maryland
U. S. PHS Public Advisory Groups	2,850	-	-	2,850	Maryland
Dana-Farber Cancer Institute	14,647	5	-	14,652	Massachusetts
Harvard University	12,344	123	-	12,467	Massachusetts
Massachusetts Institute of Technology	9,246	149	-	9,395	Massachusetts
Massachusetts General Hospital	5,628	248	-	5,876	Massachusetts
Tufts University	2,698	-	-	2,698	Massachusetts
Boston University	2,185	-	-	2,185	Massachusetts
University of Michigan	4,259	427	-	4,686	Michigan
Michigan Cancer Foundation	2,008	2,250	-	4,258	Michigan
Wayne State University	1,627	380	-	2,007	Michigan
Mayo Foundation	5,384	1,819	-	7,203	Minnesota
University of Minnesota	5,654	889	-	6,543	Minnesota
Washington University	3,577	-	-	3,577	Missouri
University of Nebraska System	2,565	-	-	2,565	Nebraska
Dartmouth College	3,315	-	607	3,922	New Hampshire

NAME OF INSTITUTION	GRANTS	CONTRACTS	CONSTRUCTION	TOTAL	STATE
University of Medicine and Dentistry of New Jersey	\$ 2,470	\$ 129	\$ -	\$ 2,599	New Jersey
Sloan-Kettering Institute for Cancer Research	21,138	422	-	21,560	New York
New York State Department of Health	11,677	246	-	11,923	New York
Columbia University	11,052	-	-	11,052	New York
Yeshiva University	8,013	276	328	8,617	New York
New York University	8,220	-	-	8,220	New York
University of Rochester	7,776	-	-	7,776	New York
Memorial Hospital for Cancer and Allied Diseases	5,479	1,485	-	6,964	New York
American Health Foundation	6,291	451	-	6,742	New York
State University of New York/Mt. Sinai School of Medicine ..	6,068	216	-	6,284	New York
Cold Spring Harbor Laboratory	4,935	-	-	4,935	New York
City University of New York	4,709	-	-	4,709	New York
Rockefeller University	4,357	-	-	4,357	New York
Cornell University	3,270	324	-	3,594	New York
Frontier Science and Technology Research Foundation	-	2,371	-	2,371	New York
Duke University	10,365	807	-	11,172	North Carolina
University of North Carolina System	4,672	-	-	4,672	North Carolina
Wake Forest University	2,203	-	-	2,203	North Carolina
Ohio State University	3,896	552	-	4,448	Ohio
Battelle Memorial Institute	511	2,980	-	3,491	Ohio
Case Western Reserve University	2,856	-	-	2,856	Ohio
Institute for Cancer Research	8,922	5	-	8,927	Pennsylvania
Wistar Institute of Anatomy and Biology	7,493	-	-	7,493	Pennsylvania
University of Pennsylvania	6,706	33	-	6,739	Pennsylvania
University of Pittsburgh	4,495	1,965	-	6,460	Pennsylvania
Pennsylvania State University	4,224	-	-	4,224	Pennsylvania
Temple University	3,779	-	-	3,779	Pennsylvania
Fox Chase Cancer Center	1,496	1,517	-	3,013	Pennsylvania
Children's Hospital of Philadelphia	2,002	-	-	2,002	Pennsylvania
St. Jude Children's Research Hospital	5,667	-	-	5,667	Tennessee
Vanderbilt University	2,426	91	-	2,517	Tennessee
University of Tennessee System	2,166	-	-	2,166	Tennessee
University of Texas System	21,507	1,347	-	22,854	Texas
Baylor College of Medicine	5,046	-	-	5,046	Texas
Cancer Therapy and Research Center	477	1,613	-	2,090	Texas
Utah State Higher Education System	4,522	1,405	-	5,927	Utah
University of Vermont and State Agricultural College	2,538	146	-	2,684	Vermont
Virginia Commonwealth University	2,003	-	-	2,003	Virginia
Fred Hutchinson Cancer Research Center	11,744	2,135	-	13,879	Washington
University of Washington	4,471	875	-	5,346	Washington
University of Wisconsin System	13,623	1,024	-	14,647	Wisconsin

TOTALS	\$492,607	\$100,410	\$1,887	\$594,904	
PERCENT OF TOTAL AWARDED ABOVE	82.8	16.9	0.3	100.0	
TOTAL NCI FISCAL YEAR 1983 OBLIGATIONS	\$986,811				
PERCENT OF NCI TOTAL OBLIGATIONS	49.9	10.2	0.2	60.3	

DISTRIBUTION OF NCI CONTRACTS — FISCAL YEAR 1983

PROGRAM DISTRIBUTION				
PERCENT OF TOTAL NUMBER OF CONTRACTS	NUMBER OF CONTRACTS	NCI PROGRAM AREA	THOUSANDS OF DOLLARS	PERCENT OF TOTAL DOLLARS
4.4	23	Division of Cancer Biology and Diagnosis	\$ 5,043	3.1
48.0	253	Division of Cancer Treatment	54,676	34.1
27.8	146	Division of Cancer Etiology	41,981	26.2
18.8	99	Division of Cancer Prevention and Control	27,052	16.9
1.0	5	Office of the Director	31,528	19.7
526		TOTALS	\$160,280	


INSTITUTIONAL DISTRIBUTION				
PERCENT OF TOTAL NUMBER OF CONTRACTS	NUMBER OF CONTRACTS	TYPE OF INSTITUTION	THOUSANDS OF DOLLARS	PERCENT OF TOTAL DOLLARS
34.4	181	Profit-Making	\$ 71,369	44.5
24.1	127	Academic	29,301	18.3
27.8	146	Non-Profit	39,582	24.7
8.6	11	State and Local Government	3,209	8.7
2.1	16	Foreign	2,863	2.0
3.0				1.8
526		TOTALS	\$160,280	

NOTE: Excludes contracts that are not in direct support of research or control, such as Cancer Communications, Program Planning, and Construction contracts.

DISTRIBUTION OF THE GRANT DOLLAR — FISCAL YEAR 1983

(DOLLARS IN THOUSANDS)

TOTAL GRANT OBLIGATIONS: \$593,344



FOREIGN RESEARCH GRANTS AND CONTRACTS—FISCAL YEAR 1983

	NUMBER OF GRANTS	GRANT DOLLARS AWARDED	NUMBER OF CONTRACTS	CONTRACT DOLLARS AWARDED	TOTAL DOLLARS AWARDED	PERCENT OF TOTAL AMOUNT AWARDED
Australia	4	\$ 178,225	—	\$ —	\$ 178,225	2.5
Belgium	1	219,555	1	199,286	418,841	5.8
Canada	18	1,162,092	2	41,537	1,203,629	16.8
China	—	—	1	305,442	305,442	4.3
Denmark	1	96,560	—	—	96,560	1.4
Finland	2	94,262	—	—	94,262	1.3
France	2	347,717	1	908,000	1,255,717	17.5
Germany	2	114,800	—	—	114,800	1.6
Ghana	—	—	1	35,000	35,000	0.5
Israel	11	743,870	2	261,918	1,005,788	14.0
Italy	1	35,596	—	—	35,596	0.5
Jamaica	—	—	1	216,360	216,360	3.0
Japan	—	—	4	566,815	566,815	7.9
Korea	1	12,449	—	—	12,449	0.2
South Africa	1	42,370	—	—	42,370	0.6
Sweden	7	619,402	—	—	619,402	8.6
Switzerland	2	191,778	—	—	191,778	2.7
Tanzania	—	—	1	58,043	58,043	0.8
United Kingdom	6	445,193	2	271,029	716,222	10.0
TOTAL	59	\$4,303,869¹	16	\$2,863,430	\$7,167,299	100.0

¹Excludes grants for resource manpower development: France—\$789; Israel—\$18,468; Sweden—\$3,695.

APPROPRIATIONS OF THE NCI 1938-1984

1938\$ 400,000
 1939 400,000

1940 THROUGH 1946 \$3,879,570

1947 1,820,900
 1948 14,500,000
 1949 22,000,000

0.16%
\$21,000,470

1950 THROUGH 1956 \$149,481,750

1957 48,432,000
 1958 56,402,000
 1959 75,268,000

2.13%
\$276,315,750

1960 THROUGH 1966 \$958,954,000

1967 175,656,000
 1968 183,356,000
 1969 185,149,500
 1970 190,486,063
 1971 230,383,000

10.72%
\$1,393,234,000

4.67%
\$606,018,563

82.32%
\$10,693,918,500

1972\$ 378,794,000
 1973 492,205,000
 1974 551,191,500
 1975 691,666,000
 1976 761,727,000¹
 "TQ" 152,901,000²
 1977 815,000,000
 1978 872,388,000
 1979 937,129,000³
 1980 1,000,000,000⁴
 1981 989,355,000⁵
 1982 986,617,000⁶
 1983 987,642,000⁷
 1984 1,077,303,000⁸

TOTAL (1938-1984) \$12,990,487,283

TRANSITION QUARTER ("TQ")— July 1, 1976 through September 30, 1976
 —The Interim Period in the changing of the Federal Fiscal Year from July 1 through June 30, to October 1 through September 30.

¹ Includes \$18,163,000 for training funds provided by Continuing Resolution.

² Includes \$3,201,000 for training funds provided by Continuing Resolution.

³ Includes \$20,129,000 for training funds provided by Continuing Resolution.

⁴ 1980 appropriation authorized under a Continuing Resolution.

⁵ Reflects 1981 rescission of \$11,975,000.

⁶ Amount included in Continuing Resolution. Includes \$47,988,000 transferred to the National Institute of Environmental Health Sciences for the National Toxicology Program.

⁷ Appropriated under Continuing Resolution and Supplemental Appropriation Bill.


⁸ Includes \$23,861,000 for training funds provided by Continuing Resolution.

COMPARISON OF DOLLARS, POSITIONS AND SPACE

FISCAL YEAR	DOLLARS			POSITIONS			SPACE		
	OBLIGATIONS (\$000's)	PERCENT OF INCREASE OVER BASE YEAR	PERCENT OF INCREASE OVER PRIOR YEAR	ACTUAL FULL-TIME PERMANENT EMPLOYEES	PERCENT OF INCREASE OVER BASE YEAR	PERCENT OF INCREASE OVER PRIOR YEAR	ALLOCATED SPACE (SQUARE FEET)*	PERCENT OF INCREASE OVER BASE YEAR	PERCENT OF INCREASE OVER PRIOR YEAR
1971	232,855	Base Year	—	1426	Base Year	—	321,230	Base Year	—
1972	378,636	62.6	62.6	1665	16.8	16.8	329,587	2.6	2.6
1973	431,245	85.2	13.9	1736	21.7	4.3	357,972	11.4	8.6
1974	581,149	149.6	34.8	1805	26.6	4.0	381,436	18.7	6.6
1975	699,320	200.3	20.3	1849	29.7	2.4	382,485	19.1	0.2
1976	760,751	226.7	8.8	1955	37.1	5.7	387,324	20.6	1.3
1977	814,957	250.0	7.1	1986	39.3	1.6	428,285	33.3	10.6
1978	872,369	275.0	7.2	1969	38.1	-0.9	491,725	53.1	14.8
1979	936,696	302.3	7.4	1973	38.4	0.2	493,156	53.5	0.3
1980	998,047	328.6	6.5	1837	28.8	-6.7	467,730	45.6	-5.2
1981	989,338	324.9	-0.9	1815	27.3	-1.2	472,633	47.1	1.0
1982	986,564	323.7	-0.3	1703	19.4	-6.2	477,782	48.7	1.1
1983	986,811	323.8	0.02	1731	21.9	1.6	484,093	50.7	1.3

*Does not include the Frederick Cancer Research Facility.

NATIONAL CANCER INSTITUTE OBLIGATIONS AND OUTLAYS



OBLIGATIONS: Orders placed, grants and contracts awarded, salaries earned and similar financial transactions which legally utilize or reserve an appropriation for expenditure.

OUTLAYS: Payments (cash or checks) made from current or prior year appropriations.

NCI TOTAL RESEARCH PROJECTS — 1978-1983¹

(DOLLARS IN THOUSANDS)

FISCAL YEAR

TYPE AWARD	REQUESTED		RECOMMENDED		AWARDED		PERCENT FUNDED ²
	NUMBER	AMOUNT	NUMBER	AMOUNT	NUMBER	AMOUNT	
1978							
Competing							
New	1,936	\$197,460	1,310	\$ 89,506	522	\$ 41,386	39.8
Renewal	719	122,158	610	68,020	348	45,624	57.0
Board Supplement	50	5,388	31	3,545	24	3,302	77.4
Subtotal	2,705	\$325,006	1,951	\$161,071	894	\$ 90,312	45.8
Noncompeting					1,376	160,433	
Total					2,270	\$250,745	
1979							
Competing							
New	1,979	\$202,206	1,436	\$108,264	565	\$ 50,351	39.3
Renewal	613	121,689	556	78,166	314	56,651	56.5
Board Supplement	42	4,313	27	1,501	21	1,033	77.8
Subtotal	2,634	\$328,208	2,019	\$187,931	900	\$108,035	44.6
Noncompeting					1,493	177,097	
Total					2,393	\$285,132	
1980							
Competing							
New	1,913	\$219,207	1,403	\$117,167	461	\$ 45,303	32.9
Renewal	593	115,053	550	73,680	293	45,802	53.3
Board Supplement	43	2,619	38	1,492	29	1,261	76.3
Subtotal	2,549	\$336,879	1,991	\$192,339	783	\$ 92,366	39.3
Noncompeting					1,762	228,959	
Total					2,545	\$321,325	
1981							
Competing							
New	2,017	\$277,145	1,594	\$156,704	483	\$ 53,004	30.3
Renewal	687	131,355	653	91,034	311	48,122	47.6
Board Supplement	61	3,776	47	1,738	32	940	68.1
Subtotal	2,765	\$412,276	2,294	\$249,476	826	\$102,066	36.0
Noncompeting					1,802	253,389	
Total					2,628	\$355,455	
1982							
Competing ³							
New	2,187	\$308,153	1,784	\$189,245	434	\$ 47,224	24.3
Renewal	730	174,573	706	117,099	323	50,186	45.7
Board Supplement	28	2,266	24	1,289	4	86	16.7
Subtotal	2,945	\$484,992	2,514	\$307,633	761	\$ 97,496	30.3
Noncompeting					1,797	260,853	
Total					2,558	\$358,349	
1983							
Competing ³							
New	2,229	\$323,572	1,844	\$215,945	529	\$55,316	28.7
Renewal	783	160,881	763	113,664	358	56,698	46.9
Board Supplement	23	2,492	15	727	3	110	20.0
Subtotal	3,035	\$486,945	2,622	\$330,336	890	\$112,124	33.9
Noncompeting					1,923	294,019	
Total					2,813	\$406,143	

¹Includes R01 traditional grants, P01 program projects, R23 new investigator research awards, R01 and U01 awards of RFA's, and R43/R44 Small Business Innovative Research awards.

²Percent Funded: Number Awarded ÷ Number Recommended.

³Because of fiscal restraints, grants were awarded below recommended levels.



National Cancer Institute